Diffusion basis spectrum imaging for identifying pathologies in MS subtypes.

Area of Science:

• Neuroimaging
• Biomarkers
• Multiple Sclerosis Research

Background:

• Multiple Sclerosis (MS) involves complex neuropathologies affecting white matter.
• Current biomarkers may not fully capture the spectrum of MS pathology.
• Diffusion Basis Spectrum Imaging (DBSI) offers advanced modeling of tissue microstructure.

Purpose of the Study:

• To evaluate Diffusion Basis Spectrum Imaging (DBSI) as a noninvasive biomarker for multiple sclerosis (MS) neuropathology.
• To correlate DBSI metrics with clinical MS subtypes and lesion characteristics.
• To compare the efficacy of DBSI metrics against traditional measures like lesion volume.

Main Methods:

• Utilized DBSI to analyze brain white matter lesions and normal-appearing corpus callosum in 55 individuals with MS.
• Employed clinical MS subtypes as surrogates for underlying neuropathologies.
• Assessed metrics including restricted isotropic fraction, fiber fraction, radial diffusivity, and nonrestricted isotropic fraction.

Main Results:

• Restricted isotropic fraction and fiber fraction were key DBSI metrics for classifying MS using white matter lesions, outperforming lesion volume.
• In normal-appearing corpus callosum, fiber fraction, radial diffusivity, and nonrestricted isotropic fraction were significant predictors.
• DBSI metrics provided insights into cellularity, axonal density, myelination, and edema.

Conclusions:

• DBSI demonstrates potential as a noninvasive biomarker for assessing MS neuropathology.
• Specific DBSI metrics can differentiate MS subtypes and reflect distinct pathological processes.
• Further research is warranted to validate DBSI's role in clinical MS management.